Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year net income growth rate
Percentile
P13
Within normal range
vs 5Y Ago
-1.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -42.15% |
| Q3 2025 | 4.92% |
| Q2 2025 | 72.08% |
| Q1 2025 | -11.88% |
| Q4 2024 | -31.55% |
| Q3 2024 | -6.40% |
| Q2 2024 | 98.38% |
| Q1 2024 | -37.74% |
| Q4 2023 | 15.06% |
| Q3 2023 | 4.07% |
| Q2 2023 | 18.42% |
| Q1 2023 | -31.68% |
| Q4 2022 | -9.01% |
| Q3 2022 | 54.41% |
| Q2 2022 | -12.47% |
| Q1 2022 | -56.33% |
| Q4 2021 | 36.56% |
| Q3 2021 | -47.33% |
| Q2 2021 | 177.88% |
| Q1 2021 | -2.96% |
| Q4 2020 | 36.47% |
| Q3 2020 | -6.15% |
| Q2 2020 | 43.66% |
| Q1 2020 | -21.14% |
| Q4 2019 | 18.28% |
| Q3 2019 | 246.76% |
| Q2 2019 | -58.12% |
| Q1 2019 | -43.80% |
| Q4 2018 | 37.96% |
| Q3 2018 | 7.84% |
| Q2 2018 | 15.36% |
| Q1 2018 | 175.46% |
| Q4 2017 | -55.32% |
| Q3 2017 | 0.15% |
| Q2 2017 | 55.76% |
| Q1 2017 | -1.65% |
| Q4 2016 | -4.41% |
| Q3 2016 | 34.95% |
| Q2 2016 | 18.39% |
| Q1 2016 | 6.93% |